Playback speed
10 seconds
ESMO 2024 Insights: Final OS from the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo with Standard Cx + Bev in Ovarian Cancer Patients with Platinum-Sensitive Relapse
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Jean-Emmanuel Kurtz
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Jean-Emmanuel Kurtz
0 views
September 26, 2024
Login to view comments.
Click here to Login